Pfizer vs. Gilead: Which Pharma Stock Wins for Growth?
Two pharma giants, one portfolio slot. Here's how Pfizer and Gilead stack up on growth potential right now.
If you're hunting for pharma exposure, you're probably eyeing Pfizer and Gilead Sciences. Both are household names. Both pay dividends. But their growth stories are headed in very different directions, and picking the wrong one could cost you.
Pfizer built its recent empire on COVID products — vaccines, antivirals, the whole pandemic playbook. The problem? That tailwind is fading fast. The company is now leaning hard on acquisitions and its oncology pipeline to replace that lost revenue. It's a big bet, and execution risk is real.
Read more Gulf Stock Markets Climb as Oil Price Gains Boost Mood →
Gilead, meanwhile, has quietly built a more durable foundation. Its HIV franchise keeps printing cash, and its oncology push — particularly in cell therapy — is gaining traction. Less flashy than Pfizer's headline moves, but arguably steadier. Investors who want predictable cash flows tend to favor that kind of story.
The honest take: Pfizer carries more upside if its pipeline delivers, but also more downside if it doesn't. Gilead is the slower, steadier play with a defensible core business. Your choice really comes down to your risk tolerance and time horizon. Momentum traders might lean Pfizer. Income-focused, long-term holders might sleep better with Gilead.
Both stocks deserve a spot on your watchlist, but only one deserves a spot in your portfolio right now — and that answer is different for every trader. Continue reading at Yahoo Finance.
